Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine. NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine.

Liver. 1997 Apr;17(2):103-6. Unique Identifier : AIDSLINE MED/97284205
Honkoop P; de Man RA; Zondervan PE; Schalm SW; Department of Internal Medicine II, (Section Hepatology), Erasmus; University Hospital, Rotterdam, The Netherlands.

Abstract: Lamivudine is an oral nucleoside analogue with strong antiviral activity against hepatitis B virus (HBV). In previous clinical studies, a course of lamivudine for 4-12 weeks induced a profound decrease in HBV viraemia with excellent tolerance, but data on histology have not yet been reported. We studied the liver histology of 13 patients with stable chronic HBV infection treated with 25 mg, 100 mg or 300 mg lamivudine daily for 6 months. All patients became HBV-DNA negative during treatment. The paired biopsies taken at entry and during treatment were scored by two independent observers, using the components of the histology activity index (HAI) and fibrosis (modified Knodell). The items scored were piecemeal necrosis, focal necrosis, confluent necrosis, portal inflammation and fibrosis. Before treatment, the biopsies yielded a mean HAI of 4.4 (+/- 0.8), which decreased to HAI 2.8 (+/- 0.5) during treatment. An analysis of the individual components of the classification system showed a significant decrease in piecemeal necrosis from a pre-treatment 1.4 (+/- 0.3) to 0.8 (+/- 0.1) during treatment (p = 0.02). Although a trend was found for the other components, it was not statistically significant, probably due to the number of pairs examined. In conclusion these results suggest that prolonged suppression of viral replication by lamivudine can improve liver histology. In contrast to previously published reports on alpha-interferon therapy, this study indicates that the improvement in liver histology with lamivudine is independent of HBe-seroconversion.
Keywords: *Antiviral Agents/ADMINISTRATION & DOSAGE *Hepatitis B/PATHOLOGY *Hepatitis B Virus *Lamivudine/ADMINISTRATION & DOSAGE *Liver/PATHOLOGYKWDantiviralagents/administration&dosageKWDhepatitisb/pathologyKWDhepatitisbvirusKWDlamivudine/administration&dosageKWDliver/pathology
970930
M9791304

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .